Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythropoietin add-on versus placebo in amyotrophic lateral sclerosis
2005-005873-31Phase 2Completed
- Sponsor
- Carlo Besta Neurological Institute
- Start
- Mar 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Erythropoietin add-on with Placebo add-on (2 arms). Primary endpoints: ALSFRS-R slope during treatment versus lead-in period and Safety. Started Mar 2006; status: completed.
02
Drugs
erythropoietin
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2005-005873-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005873-31.